Indeed, in clinical trials, blockade of the PD-1/PD-L1 pathway has significantly boosted antitumor immunity and prolonged patient survival across multiple tumor types, including colon cancer, melanoma, lung cancer, renal cell carcinoma, ovarian cancer, head and neck cancer, and breast cancer [4,5,6,7,8,9,10]. This evidence concerns the gene CD274 and colonic neoplasm.